These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 33865453)

  • 1. Association between menopausal hormone therapy, mammographic density and breast cancer risk: results from the E3N cohort study.
    Fornili M; Perduca V; Fournier A; Jérolon A; Boutron-Ruault MC; Maskarinec G; Severi G; Baglietto L
    Breast Cancer Res; 2021 Apr; 23(1):47. PubMed ID: 33865453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is breast cancer risk the same for all progestogens?
    Stute P
    Arch Gynecol Obstet; 2014 Aug; 290(2):207-9. PubMed ID: 24838289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of postmenopausal hormone therapies and risk of histology- and hormone receptor-defined breast cancer: results from a 15-year prospective analysis of NIH-AARP cohort.
    Wang SM; Pfeiffer RM; Gierach GL; Falk RT
    Breast Cancer Res; 2020 Nov; 22(1):129. PubMed ID: 33239054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence.
    Collaborative Group on Hormonal Factors in Breast Cancer
    Lancet; 2019 Sep; 394(10204):1159-1168. PubMed ID: 31474332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Menopausal Hormone Therapy use and breast cancer risk by receptor subtypes: Results from the New South Wales Cancer Lifestyle and EvaluAtion of Risk (CLEAR) study.
    Salagame U; Banks E; O'Connell DL; Egger S; Canfell K
    PLoS One; 2018; 13(11):e0205034. PubMed ID: 30403669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comprehensive evaluation of interaction between genetic variants and use of menopausal hormone therapy on mammographic density.
    Rudolph A; Fasching PA; Behrens S; Eilber U; Bolla MK; Wang Q; Thompson D; Czene K; Brand JS; Li J; Scott C; Pankratz VS; Brandt K; Hallberg E; Olson JE; Lee A; Beckmann MW; Ekici AB; Haeberle L; Maskarinec G; Le Marchand L; Schumacher F; Milne RL; Knight JA; Apicella C; Southey MC; Kapuscinski MK; Hopper JL; Andrulis IL; Giles GG; Haiman CA; Khaw KT; Luben R; Hall P; Pharoah PD; Couch FJ; Easton DF; Dos-Santos-Silva I; Vachon C; Chang-Claude J
    Breast Cancer Res; 2015 Aug; 17(1):110. PubMed ID: 26275715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mammographic density, response to hormones, and breast cancer risk.
    Boyd NF; Melnichouk O; Martin LJ; Hislop G; Chiarelli AM; Yaffe MJ; Minkin S
    J Clin Oncol; 2011 Aug; 29(22):2985-92. PubMed ID: 21709206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor characteristics and family history in relation to mammographic density and breast cancer: The French E3N cohort.
    Maskarinec G; Dartois L; Delaloge S; Hopper J; Clavel-Chapelon F; Baglietto L
    Cancer Epidemiol; 2017 Aug; 49():156-160. PubMed ID: 28697417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between menopausal hormone therapy and mortality after breast cancer The MARIEplus study, a prospective case cohort.
    Obi N; Heinz J; Seibold P; Vrieling A; Rudolph A; Chang-Claude J; Berger J; Flesch-Janys D
    Int J Cancer; 2016 May; 138(9):2098-108. PubMed ID: 26649645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Race, Menopausal Hormone Therapy, and Invasive Breast Cancer in the Carolina Breast Cancer Study.
    DeBono NL; Robinson WR; Lund JL; Tse CK; Moorman PG; Olshan AF; Troester MA
    J Womens Health (Larchmt); 2018 Mar; 27(3):377-386. PubMed ID: 28570827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction between current vitamin D supplementation and menopausal hormone therapy use on breast cancer risk: evidence from the E3N cohort.
    Cadeau C; Fournier A; Mesrine S; Clavel-Chapelon F; Fagherazzi G; Boutron-Ruault MC
    Am J Clin Nutr; 2015 Oct; 102(4):966-73. PubMed ID: 26354532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction of mammographic breast density with menopausal status and postmenopausal hormone use in relation to the risk of aggressive breast cancer subtypes.
    Yaghjyan L; Tamimi RM; Bertrand KA; Scott CG; Jensen MR; Pankratz VS; Brandt K; Visscher D; Norman A; Couch F; Shepherd J; Fan B; Chen YY; Ma L; Beck AH; Cummings SR; Kerlikowske K; Vachon CM
    Breast Cancer Res Treat; 2017 Sep; 165(2):421-431. PubMed ID: 28624977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of mammographic density with hormone receptors in invasive breast cancers: results from a case-only study.
    Heusinger K; Jud SM; Häberle L; Hack CC; Adamietz BR; Meier-Meitinger M; Lux MP; Wittenberg T; Wagner F; Loehberg CR; Uder M; Hartmann A; Schulz-Wendtland R; Beckmann MW; Fasching PA
    Int J Cancer; 2012 Dec; 131(11):2643-9. PubMed ID: 22392346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of breast cancer by type of menopausal hormone therapy: a case-control study among post-menopausal women in France.
    Cordina-Duverger E; Truong T; Anger A; Sanchez M; Arveux P; Kerbrat P; Guénel P
    PLoS One; 2013; 8(11):e78016. PubMed ID: 24223752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic or Vaginal Hormone Therapy After Early Breast Cancer: A Danish Observational Cohort Study.
    Cold S; Cold F; Jensen MB; Cronin-Fenton D; Christiansen P; Ejlertsen B
    J Natl Cancer Inst; 2022 Oct; 114(10):1347-1354. PubMed ID: 35854422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort.
    Fournier A; Mesrine S; Dossus L; Boutron-Ruault MC; Clavel-Chapelon F; Chabbert-Buffet N
    Breast Cancer Res Treat; 2014 Jun; 145(2):535-43. PubMed ID: 24781971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between menopausal hormone therapy and breast cancer: A nationwide population-based cohort study.
    Yuk JS
    Int J Gynaecol Obstet; 2024 Aug; 166(2):735-744. PubMed ID: 38469634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Menopausal hormone therapy use in relation to breast cancer incidence in 11 European countries.
    Antoine C; Ameye L; Paesmans M; de Azambuja E; Rozenberg S
    Maturitas; 2016 Feb; 84():81-8. PubMed ID: 26654400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of mammographic density with the proliferation marker Ki-67 in a cohort of patients with invasive breast cancer.
    Heusinger K; Jud SM; Häberle L; Hack CC; Fasching PA; Meier-Meitinger M; Lux MP; Hagenbeck C; Loehberg CR; Wittenberg T; Rauh C; Wagner F; Uder M; Hartmann A; Schulz-Wendtland R; Beckmann MW; Wachter DL
    Breast Cancer Res Treat; 2012 Oct; 135(3):885-92. PubMed ID: 22936391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Body mass index, mammographic density, and breast cancer risk by estrogen receptor subtype.
    Shieh Y; Scott CG; Jensen MR; Norman AD; Bertrand KA; Pankratz VS; Brandt KR; Visscher DW; Shepherd JA; Tamimi RM; Vachon CM; Kerlikowske K
    Breast Cancer Res; 2019 Apr; 21(1):48. PubMed ID: 30944014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.